How Long Will It Take to Launch an Effective Helicobacter pylori Vaccine for Humans?
Songhui Li1, Wenfeng Zhao2, Lei Xia3
1Jiangsu Key Laboratory of Bioactive Natural Product Research and State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, 210009 People's Republic of China.
Insights
Developing a Helicobacter pylori (H. pylori) vaccine remains challenging despite decades of research. This review examines candidate antigens, adjuvants, and delivery systems, highlighting obstacles to H. pylori vaccine development.
Area of Science:
- Microbiology
- Immunology
- Vaccinology
Background:
- Helicobacter pylori infection is a persistent childhood infection leading to stomach diseases.
- Antibiotic treatments for H. pylori are effective but face challenges like relapse and drug resistance.
- A vaccine offers a promising strategy for H. pylori prevention and therapy.
Purpose of the Study:
- To review the progress in H. pylori vaccine research.
- To analyze candidate antigens, immunoadjuvants, and delivery systems.
- To discuss challenges and future directions for H. pylori vaccine development.
Main Methods:
- Comprehensive literature review of H. pylori vaccine research.
- Analysis of preclinical and clinical trial data.
- Discussion of factors influencing vaccine efficacy and market availability.
Main Results:
- Decades of research have yielded numerous candidate H. pylori vaccines, but none have reached the market.
- Various antigens, adjuvants, and delivery systems have been explored with mixed results.
- Clinical trials have shown both encouraging and disappointing outcomes.
Conclusions:
- The development of an effective H. pylori vaccine faces significant hurdles.
- Further research into optimal antigen selection, adjuvant formulation, and delivery methods is crucial.
- Addressing the reasons for clinical trial failures is essential for future H. pylori vaccine success.
Abstract:
Helicobacter pylori infection often occurs in early childhood, and can last a lifetime if not treated with medication. H. pylori infection can also cause a variety of stomach diseases, which can only be treated with a combination of antibiotics. Combinations of antibiotics can cure H. pylori infection, but it is easy to relapse and develop drug resistance. Therefore, a vaccine is a promising strategy for prevention and therapy for the infection of H. pylori. After decades of research and development, there has been no appearance of any H. pylori vaccine reaching the market, unfortunately. This review summarizes the aspects of candidate antigens, immunoadjuvants, and delivery systems in the long journey of H. pylori vaccine research, and also introduces some clinical trials that have displayed encouraging or depressing results. Possible reasons for the inability of an H. pylori vaccine to be available over the counter are cautiously discussed and some propositions for the future of H. pylori vaccines are outlined.
Related Concept Videos
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
01:51Vaccinations
01:28Preclinical Development: Overview